Anti-TNFα therapy in immune-mediated subfertility: State of the art

Journal of Reproductive Immunology

Volumn 85, Issue 1, 2010, Pages 15-24

  Clark, David A ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Anti TNF alpha; Controlled clinical trials; Evidence based medicine; Infertility; Recurrent spontaneous abortion

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ETANERCEPT; GAMMA INTERFERON; HEPARIN; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 10; PLACEBO; REMICAID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ANAPHYLAXIS; ARTICLE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DATA ANALYSIS; DEMYELINATION; DISEASE ASSOCIATION; DISEASE MODEL; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; EVIDENCE BASED MEDICINE; FEMALE INFERTILITY; FEMALE SUBFERTILITY; FERTILIZATION IN VITRO; HUMAN; IMMUNE RESPONSE; INFECTION; INFORMED CONSENT; LYMPHOMA; MEDICAL LITERATURE; METHODOLOGY; NONHUMAN; OBSERVATIONAL STUDY; PATHOPHYSIOLOGY; PREGNANCY; PRIORITY JOURNAL; RECURRENT ABORTION; RELIABILITY; RISK ASSESSMENT; SPONTANEOUS ABORTION; SQUAMOUS CELL CARCINOMA; TERATOGENICITY; TH1 CELL; TH2 CELL; TREATMENT FAILURE; TUBERCULOSIS; ANIMAL; DRUG ANTAGONISM; FEMALE; IMMUNOLOGY; MOUSE; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFERTILITY, FEMALE; MICE; PREGNANCY; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77952096811     PISSN: 01650378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jri.2010.01.007     Document Type: Article

References (82)

1. Allessandri C., Scrivo R., Spinelli F.R., Ceccarelli F., Magrini L., et al. Autoantibody production in anti-TNFα-treated patients. Ann. N. Y. Acad. Sci. 2007, 1110:319-329.
2. Andalib A., Rezaie A., Oreizy F., Shafiei K., Baluchi S. A study on stress, depression and NK cytotoxic potential in women with recurrent spontaneous abortion. Iranian J. Allergy Asthma Immunol. 2006, 5:9-16.
3. Arck P.C., Rose M., Hertwig K., Hagen E., Hildebrandt M., Klapp B.F. Stress and immune mediators in miscarriage. Hum. Reprod. 2001, 16:1505-1551.
4. Arck P.C., Rucke M., Rose M., Szekeres-Bartho J., Douglas A.J., Pritsch M., et al. Early risk factors for miscarriage: a prospective cohort study in pregnant women. Reprod. Biomed. Online 2008, 17:101-113.
5. Bayry J., Siberil S., Triebel F., Tough D.F., Kaveri S.V. Rescuring CD4+CD25+ regulatory T cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy. Drug Discov. Today 2007, 12:548-552.
6. Benson K., Hartz A.J. A comparison of observational studies and randomized controlled trials. N. Engl. J. Med. 2000, 342:1878-1886.
7. Boomsma C.M., Kavelaars A., Eijkemans M.J.C., Lentjes E.G., Fauser B.C.J.M., et al. Endometrial secretion analysis identifies a cytokine profile predictive of pregnancy in IVF. Hum. Reprod. 2009, 34:1427-1435.
8. Carp H.J.A. Abstracts of Contributors' individual data submitted to the worldwide prospective observation study on immunotherapy of treatment of recurrent spontaneous abortion. Am. J. Reprod. Immunol. 1994, 32:271-273.
9. Carter J., Ladhani A., Ricca L.R., Valeriano J., Vaset F.B. A safety assessment of TNF antagonists during pregnancy: a review of the FDA database. J. Rheumatol. 2009, 36:635-641.
10. Chaouat G. Should we re-examine the status of lymphocyte alloimmunization therapy for recurrent spontaneous abortion? Am. J. Reprod. Immunol. 2003, 50:433-438.
11. Chaouat G., Assal-Meliani A., Martal J., Raghupathy R., Elliot J.F., Mosmann T., Wegmann T.G. IL-10 prevents naturally occurring fetal loss in the CBA x DBA/2 mating combination, and local defect in IL-10 production in this abortion-prone combination is corrected by in vivo injection of IFNtau. J. Immunol. 1995, 154:4261-4268.
12. Clark D.A. Is there any evidence for immunologically mediated or immunologically modifiable early pregnancy failure?. J. Assist. Reprod. Genet. 2003, 20:63-72.
13. Clark D.A. Shall we properly re-examine the status of allogeneic lymphocyte immunotherapy for recurrent early pregnancy failure?. Am. J. Reprod. Immunol. 2004, 51:7-15.
14. Clark D.A. Is paternal leukocyte immunotherapy indicated?. Recurrent Pregnancy Loss 2007, 179-184. Informa Health Care, Oxon, UK. H.J.A. Carp (Ed.).
15. Clark D.A. Immunological factors in pregnancy wastage: fact or fiction. Am. J. Reprod. Immunol. 2008, 59:277-300.
16. Clark D.A. Should anti-TNFα therapy be offered to patients with infertility and recurrent spontaneous abortion?. Am. J. Reprod. Immunol. 2009, 61:107-112.
17. Clark D.A., Croitoru K. Th1/Th2/3 imbalance due to cytokine-producing NK, γδT and NK-γδT cells in murine pregnancy decidua in success or failure of pregnancy. Am. J. Reprod. Immunol. 2001, 45:257-265.
18. Clark D.A., Daya S., Coulam C.B., Gunby J., RMIT G. Implications of trophoblast karyotype in the evidence-based approach to the understanding, investigation, and treatment of recurrent spontaneous abortion. Am. J. Reprod. Immunol. 1996, 35:495-498.
19. Clark D.A., Gunby J., Daya S. The use of allogeneic leukocytes or IV IgG for the treatment of patients with recurrent spontaneous abortions. Transfus. Med. Rev. 1997, 11:85-94.
20. Clark D.A., Coulam C.B., Stricker R.B. Is intravenous immunogloblulins (IVIG) efficacious in early pregnancy failure? A critical review and meta-analysis for patients who fail in vitro fertilization and embryo transfer (IVF). J. Assist. Reprod. Genet. 2006, 23:1-13.
21. Clark D.A., Yu G., Arck P.C., Levy G.A., Gorczynski R.M. MD-1 is a critical part of the mechanism causing Th-1 cytokine-triggered murine fetal loss syndrome. Am. J. Reprod. Immunol. 2003, 49:297-307.
22. Clark D.A., Coulam C.B., Daya S., Chaouat G. Unexplained sporadic and recurrent miscarriage in the new millennium: a critical analysis of immune mechanisms and treatments. Hum. Reprod. Update 2001, 7:501-511.
23. Collins J.A., Wrixon W., Janes L.B., Wilson E.H. Treatment-independent pregnancy among infertile couples. N. Engl. J. Med. 1983, 309:1201-1206.
24. Concato J., Shaw H., Horowitz R.E. Randomized controlled trials, observational studies, and hierarchy of research designs. N. Engl. J. Med. 2000, 342:1877-1892.
25. Coulam C.B., Roussev R. Correlation of NK cell activation and inhibition markers with NK cytotoxicity among women experiencing immunological implantation failure after in vitro fertilization and embryo transfer. J. Assist. Reprod. Genet. 2003, 20:58-62.
26. Coulam C.B., Roussev R.G. Increasing circulating T-cell activation markers are linked to subsequent implantation failure after transfer of in vitro fertilized embryos. Am. J. Reprod. Immunol. 2003, 50:340-345.
27. Coulam C.B., Stephenson M., Stern J.J., Clark D.A. Immunotherapy for recurrent pregnancy loss: analysis of results from clinical trials. Am. J. Reprod. Immunol. 1996, 35:352-359.
28. Engel S.H., Hullar T.E., Adkins D.R., Thorstad W.L., Sunwoo J.B. Temporal relationship between antitumor necrosis factor-α antibody therapy and recrudescence of head and neck squamous cell carcinoma. Laryngoscope 2008, 118:450-452.
29. Fromont A., De Seze J., Fleury M.C., Maillefert J.F., Moreau T. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine 2009, 45:55-57.
30. Fukui A., Kwak-Kim J., Ntrivalas R., Gilman-Sachs A., Lee S.K., Beaman K. Intracellular cytokine expression of peripheral blood natural killer cell subsets in women with recurrent spontaneous abortions and implantation failure. Fertil. Steril. 2008, 89:157-165.
31. Girardi G. Guilty as charged: all available evidence implicates complement's role in fetal demise. Am. J. Reprod. Immunol. 2008, 59:183-192.
32. Girardi G., Yarilin D., Thurman J.M., Holers V.M., Salmon J.E. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J. Exp. Med. 2006, 203:2165-2175.
33. Greenwold N., Jauniaux E. Collection of villus tissue under ultrasound guidance to improve cytogenetic study of early pregnancy failure. Hum. Reprod. 2002, 17:452-456.
34. Guyatt G.H., Cook D.J., Jaeshke R., Pauker S.G., Schunemann H.J. Grades of recommendation for antithrombotic agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008, 136(6 (Suppl.)):123S-132S.
35. Horton R. The rhetoric of research. BMJ 1995, 310:985-987.
36. Horton R. The hidden research paper. J. Am. Med. Assoc. 2002, 287:2775-2778.
37. Ioannidis J.P.A., Haidich A.-B., Pappa M., Pantazis N., Kokori S.I., Tektonidou M.G., et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA 2001, 286:821-830.
38. Kieszko R., Krawczyk P., Chocholska S., Bojarska-Junak A., Krol A., Rolinski J., et al. Tumor necrosis factor receptors (TNFRs) on T lymphocytes and soluble TNFRs in different clinical courses of sarcoidosis. Respiratory Medicine 2007, 101:645-680.
39. Knackstedt M., Ding J.W., Arck P.C., Hertwig K., Coulam C.B., August C., et al. Activation of the novel prothrombinase, fgl2, as a basis for the pregnancy complications spontaneous abortion and pre-eclampsia. Am. J. Reprod. Immunol. 2001, 46:196-210.
40. Kruse C., Varming K., Christiansen O.B. Prospective, serial investigations of in-vitro lymphocyte cytokine production, CD62L expression and proliferative response to microbial antigens in women with recurrent miscarriage. Hum. Reprod. 2003, 18:2465-2472.
41. Kwak-Kim J.Y., Chung-Bang H.S., Ng S.C., Ntrivales E.I., Mangubat C.P., Beaman K.D., et al. Increased T helper 1 cytokine responses by circulating T cells are present in women with recurrent pregnancy losses and in infertile women with multiple implantation failures after IVF. Hum. Reprod. 2003, 18:767-773.
42. Koren G., Inoue M. Do tumor necrosis factor inhibitors cause malformations in humans?. J. Rheumatol. 2009, 36:465-466.
43. Kuriya, B., 2008. Safety of anti-TNFα agents during pregnancy. http://www.rheumatology.utoronto.ca/Assets/Rounds/ICC+April+8th$!2c+2008.pdf.
44. Laudenslager M.L., Aasal R., Adler L., Berger C.L., Montgomery P.T., et al. Elevated cytotoxicity in combat veterans with long-term post-traumatic stress disorder: preliminary observations. Brain Behav. Immun. 1998, 12:74-79.
45. Lidz C.W., Appelbaum P.S., Joffe S., Albert J., Rosenbaum J., Simon L. Competing commitments in clinical trials. IRB: Ethics Hum. Res. 2009, 31:1-6.
46. Lozeron P., Denier C., Lacroix C., Adams D. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-α blockade. Arch. Neurol. 2009, 66:490-497.
47. Mangubat C.P., Thaker P.P., Cavalcante M., Kwak-Kim J.Y.H., Beer A.E. Etanercept and immune treatment in multiple IVF failures. Am. J. Reprod. Immunol. 2001, 45:345-346.
48. Medawar P.B. Advice to a Young Scientist 1979, Harper & Row, New York, NY, USA.
49. Montori V.M., Jaeschke R., Schunemann H.J., Bhandari M., Brozek J.L., Devereaux P.J., et al. Users' guide to detecting misleading claims in clinical research reports. BMJ 2004, 329:1093-1096.
50. Mueller-Eckhardt G., Mallmann P., Neppert J., Lattermann A., Melk A., Heine O., et al. Immunogenetic and serological investigations in nonpregnant and in pregnant women with a history of recurrent spontaneous abortions. J. Reprod. Immunol. 1994, 27:95-109.
51. Murphy S.P., Tayade C., Ashkar A.A., Hatta K., Zhang J., Croy B.A. Interferon gamma in successful pregnancies. Biol. Reprod. 2009, 80:848-859.
52. Nadkarni S., Mauri C., Ehrenstein M.R. Anti-TNFα therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-β. N. Engl. J. Med. 2007, 204:33-39.
53. Nagaeva O., Jonsson L., Mincheva-Nilsson L. Dominant IL-10 and TGF-β mRNA expression in γδT cells of human early pregnancy decidua suggests immunoregulatory potential. Am. J. Reprod. Immunol. 2002, 48:9-17.
54. Nisashima A., Shiozaki A., Myojo S., Ito M., Tatematsu M., Sakai M., et al. Granulysin produced by uterine natural killer cells induces apoptosis of extravillous trophoblasts during spontaneous abortion. Am. J. Pathol. 2008, 173:653-664.
55. Ottenbacher K. Impact of random assignment on study outcome: an empirical examination. Control. Clin. Trials 1992, 13:50-61.
56. Piccinni M.P. T cells in pregnancy. Chem. Immunol. Allergy 2005, 89:3-9.
57. Redecha P., Tilley R., Tencati M., Salmon J.E., Kirchhofer D., Mackman N., et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 2007, 110:2423-2431.
58. Redecha P., Franzke C.W., Ruf W., Mackman N., Girardi G. Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J. Clin. Invest. 2008, 118:3453-3461.
59. Redecha P., van Rooijen N., Torry D., Girardi G. Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury. Blood 2009, 113:4101-4109.
60. RMITG (Recurrent Miscarriage Immunotherapy Trialists Group) Worldwide collaborative observational study and meta-analysis on allogeneic leukocyte immunotherapy for recurrent spontaneous abortion. Am. J. Reprod. Immunol. 1994, 32:55-72.
61. Rubbert-Roth A., Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Biomed. Cent. 2009, 11(Suppl. 1):1-12.
62. Saad A.A., Symmons D.P.M., Noyce P.R., Ashcroft D.M. Risks and benefits of tumor necrosis factor-α inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J. Rheumatol. 2008, 35:883-890.
63. Scarpellini R., Sbracia M. Use of granulocyte colony-stimulating factor for the treatment of unexplained recurrent miscarriage: a randomized controlled trial. Hum. Reprod. 2009, 24:2703-2708.
64. Scarpellini R., Sbracia M., Patella A. G=CSF pharmacologic supplementation in the ART (assisted reproductive technologies) treatment cycles of low responder women. J. Reprod. Immunol. 2009, 81:158-159.
65. Shakhar K., Rosenne E., Loenwentahl R., Rosenne E., Shakhar G., Carp H., et al. High NK activity in recurrent miscarriage: what are we really measuring?. Hum. Reprod. 2006, 21:2421-2425.
66. Sheridan C. Small molecule challenges dominance of TNFα inhibitors. Nat. Biotechnol. 2008, 26:143-144.
67. Silverman S.L. From randomized trials to observational studies. Am. J. Med. 2009, 122:114-120.
68. Straus S., Haynes S., Glasziou P., Dickerson K., Guyatt G. Misunderstandings, misperceptions, and mistakes. Evidence Based Med. 2007, 12:2-3.
69. Stephenson M.D., Kutteh W., Purkiss S., Librach C., Houlihan E., Schulz P. Intravenous immunoglobulin (IVIG) for treatment of idiopathic secondary recurrent miscarriage (ISRM): a prospective, randomized, double-blinded, placebo-controlled, multi-centered study. Fertil. Steril. 2009, 92(Suppl.):S67-S68.
70. bright regulatory T cells from the peripheral blood to the decidua in human pregnancy. J. Immunol. 2008, 180:5737-5745.
71. Torchinsky A., Shepshelovich J., Orenstein H., Zaslavsky Z., Savion S., Carp H., et al. TNFα protects embryos exposed to developmental toxicants. Am. J. Reprod. Immunol. 2003, 49:159-168.
72. Tsiodras S., Samonis G., Boumpas D.T., Kontoyiannis D.P. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin. Proc. 2008, 83:181-194.
73. Vigna-Perez M., Abdul-Mendoza C., Portillo-Salazar H., Alvarado-Sanchez B., Cuevas-Orta E., Moreno-Valdes R., et al. Immune effects of therapy with adalimumab in patients with rheumatoid arthritis. Clin. Exp. Immunol. 2005, 141:372-380.
74. Vist, G.E., Bryant, D., Somerville, L., Birmingham, T, Oxman, A.D., 2008. Outcome of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate. Cochrane Database Syst. Rev (3), MR000009 (update of Cochrane Database Syst. Rev. 2007;(2):MR000009, PMID: 17443630).
75. Wegmann T.G., Lin H., Guilbert L., Mossmann T.R. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a Th2 phenomenon. Immunol. Today 1993, 14:353-356.
76. Williams G.M. Antitumor necrosis factor-α therapy and potential cancer inhibition. Eur. J. Cancer Prev. 2008, 17:169-177.
77. Winger E.E., Reed J.L. Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion. Am. J. Reprod. Immunol. 2008, 60:8-16.
78. Winger E.E., Reed J. Does " A safety assessment of TNF antagonists during pregnancy: a review of the Food and Drug Administration Database by Carter et al. properly asses risk?. J. Rheumatol. 2009, 36:2112.
79. Winger E.E., Reed J., Ashoush S., Sapna A., El-Roukhy T., Teranissi M. Treatment with adalimumab (Humira) and intravenous immunoglobulin (IVIG) improves pregnancy rates in women undergoing IVF. Am. J. Reprod. Immunol. 2009, 61:113-120.
80. Winger E.E., Rooed J.L., Ashoush S., Jadhav J., Taranissi M. Degree of Th1/Th2 cytokine elevation predicts IVF success rates in women undergoing treatment with adalimumab (Humira) and intravenous immunoglobulin for immunological infertility. J. Reprod. Immunol. 2009, 81:150.
81. Winger E.E., Reed J.L., Ashoush S., Jadhav J., Taranissi M. Birth defect rates in women using adalimumab (Humira) and intravenous immunoglobulin to treat immunologic-based infertility in IVF. J. Reprod. Immunol. 2009, 81:169-170.
82. Yamada H., Morikawa M., Kato E.H., Shimada S., Kobashi G., Minakami H. Preconceptional natural killer cell activity and percentage as predictors of biochemical pregnancy and spontaneous abortion with a normal karyotype. Am. J. Reprod. Immunol. 2003, 50:351-354.